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Abstract 
Background: NK cell cytotoxicity is regulated by the types of the interaction between killer immunoglobulin-like 
receptors (KIRs) and human leukocyte antigen (HLA) class I ligands on target cells and the different binding affinity 
of the Fcγ receptor IIIA (CD16A) for IgG-coated tumor cells. Thus, it is conceivable that KIR and CD16A gene contents 
may contribute to the function of NK cells by modulating an immune response in the colorectal carcinoma (CRC) 
microenvironment. This hypothesis is supported by recent evidence suggesting that NK cells improve the clinical 
course of CRC patients by enhancing the anti-CRC effect of CD8 + T cells. This information provides the rationale to 
test the hypothesis whether the independent KIR segregation and specificity, as well as CD16A gene polymorphisms, 
have an impact on CRC.
Methods: Using polymerase chain reaction-sequence-specific primers (PCR-SSP) and sequence-based typing (SBT), 
we investigated KIR/HLA-C complex and CD16A (48H/R/L,158V/F) gene polymorphisms in 52 CRC patients and 61 
local healthy controls (LCTRs).
Results: The allele frequency (AF) of at least five activating KIR (aKIRs) of the B haplotype (p = 0.036, OR 0.204), 
KIR2DL2 (p = 0.047, OR 0.2616), and KIR2DS2 genes (5.8 vs LCTR 13.8 % and vs. Fasano’s CTR 16.3 %, p = 0.05, OR 
0.3145), in the absence of their cognate HLA-C1 ligands, were significantly associated with a reduced genetic risk of 
CRC. In contrast, CD16A-48H polymorphism was positively associated with an increased genetic risk of CRC (p = 0.05, 
OR 2.761). The latter was also found to be correlated with advanced stages of disease [III and IV (p = 0.03, OR 3.625)].
Conclusions: Our data suggest that the analysis of aKIRs and KIR2DL2 gene and CD16A-48H may be of interest for 
the identification of individuals at reduced and increased genetic risk of CRC, respectively.
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Background
Compelling evidence suggests that a pro-inflammatory 
solid tumor microenvironment composed of CD8  +  T 
lymphocytes is associated with a favorable course of dis-
ease [1–3]. In contrast, a solid tumor microenvironment 
infiltrated by anti-inflammatory cells including tumor-
associated macrophages (TAMs) [4] and regulatory T 
cells (Tregs) [5] is an unfavorable prognostic factor, and 
it is associated with poor prognosis. However, CRC 
seems to be an exception since inflammation, regardless 
the type of cellular infiltration including TAMs [6–9] 
and Tregs [10], is associated with a favorable progno-
sis. In this context, however, the role of NK cells is still 
debated [11, 12]. The argument involving the role of NK 
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cell infiltration of solid tumors [12]. The reduced NK 
cell infiltration in the tumor bed can be, at least in part, 
explained by the detrimental effect of malignant cells on 
NK cells. Besides, there is also conflicting information 
about the clinical relevance of NK cells in CRC [13–15]. 
Recent findings, however, suggest that intra-tumor NK 
cell infiltration improves the clinical outcome of CRC 
by enhancing the protective role of tumor-infiltrating 
CD8  +  T cells [16]. In addition, loss or down-regula-
tion of HLA class I molecules on autologous CRC cells 
promotes NK cell cytotoxicity [17]. Because KIRs are 
independently segregated, an autologous KIR-HLA mis-
matched may exist. As a consequence, NK cells can trig-
ger an enhanced cytotoxicity, as compared with NK cells 
expressing self-recognizing inhibitory KIRs [18].
KIRs consist of immunoglobulin-like receptors and 
heterodimers [19]. Immunoglobulin-like KIRs, with a 
long intracellular tail (KIRL), mediate inhibitory activity 
while those with a short intracellular tail (KIRS) can func-
tion as activating molecules. The HLA-C antigens are 
the best-known KIR ligands. Based on polymorphisms 
at positions 77 and 80, in the α1-domain of the β chain, 
KIRs can be identified into two additional groups: the 
HLA-C1 that carries an asparagine residue at position 80, 
and the HLA-C2 that has a lysine residue at position 80 
[20, 21]. To date, KIR genotyping is utilized for the analy-
sis of gene content and categorization of A/B haplotypes 
as well as for prediction of NK cell reactivity in autolo-
gous and allo NK cell-based immunotherapy [22, 23]. The 
A haplotype contains several inhibitory KIR genes and 
only one activating KIR. Conversely, B haplotype displays 
more activating KIR genes. Based on the linkage disequi-
librium between particular alleles of different KIR loci, 
within the B haplotype, two gene clusters are identified. 
The first group consists of four centromeric KIR genes 
(C4 group), while the second group contains telomeric 
genes (T4 group) [24]. Recently, several studies have indi-
cated a relationship between KIR genotype and cancer, 
but there is scant information about a link between KIR 
genes and CRC [25–27].
A primary mechanism by which NK cells kill CRC cells 
is the antibody-dependent cellular cytotoxicity (ADCC). 
This function is a result of the engagement of the Fc frag-
ment of an antibody to the CD16A antigen on NK cell 
surface. The extent of ADCC relies on the binding affinity 
of the Fc fragment of the mAb to CD16A that is in turn 
regulated by CD16A polymorphisms [28]. In fact, the 
presence of valine/valine (V/V), but not valine/phenyla-
lanine (V/F) at position 158, enhances ADCC and human 
IgG1 binding to CD16A [29]. Among monoclonal anti-
bodies (mAbs), the anti-epidermal-growth factor recep-
tor (EGFR), namely cetuximab has been successfully 
utilized for targeting therapy of EGFR+  malignancies 
including CRC [30]. Furthermore, cetuximab -activated 
NK cells have been shown to exert an indirect anti-tumor 
effect by promoting tumor antigen-anti-EGFR-specific 
T cells [31]. Thus, the genetic distribution of KIRs and 
CD16A is likely to have a substantial impact on NK cell 
phenotype and function that may affect the CRC patho-
genesis. This information provides the rationale for 
testing the effect of KIR and CD16A genotypes on the 




The case–control study was performed using peripheral 
blood cells obtained from Italian CRC patients, recruited 
at the Policlinic of Tor Vergata between August 2010 and 
December 2012. This study (protocol number: 133/10) 
was approved by an independent, Institutional Review 
Board (IRB) Committee at the Teaching Hospital of Tor 
Vergata, Rome, Italy. Fifty-two CRC patients (31 males 
and 21 females), aged between 32 and 88 years, without 
a previous history of inflammatory bowel disease (IBD) 
and autoimmune diseases, were included in this protocol. 
Staging of the disease was assessed according to the path-
ological classification of tumor-node-metastasis (pTNM), 
as shown in Table  1. Control population comprised 61 
healthy subjects (26 males and 35 females) originating 
from CRC patients geographical area, hereafter referred 
to as local controls (LCTRs) and historical controls [32, 
33].
DNA extraction and KIR genotyping
Peripheral blood cell DNA was isolated using spin bind 
columns (QIAmp Blood Midi kit, Qiagen), which purify 
genomic DNA from contaminants and proteins. KIR 
genotyping was performed using PCR-SSP primers for 
17 KIR genes (KIR2DL1, 2DL2, 2DL3, 2DL4, 2DL5A, 
2DL5B, 2DS1, 2DS2, 2DS3, 2DS4del and 2DS4ins, 2DS5, 
3DL1, 3DL2, 3DL3, 3DS1 and 2DP1, 3DP1 pseudogenes) 
(Miltenyi Biotech). PCR products were visualized after a 
2 % gel electrophoresis containing ethidium bromide and 
photo-documented on a UV trans-illuminator. KIR hap-
lotypes were classified as previously reported [34].
HLA‑C allele genotyping
HLA-C typing was performed by using a sequence-
based typing (SBT) kit with a bigdye terminator chemis-
try v.1.1 (AlleleSEQR HLA-C kit, Atria) which analyzes 
the allelic polymorphisms in exons 2-4 of HLA-C gene. 
Different HLA-C alleles were divided in C1(HLA-C*01, 
03,07,08,09,10,12,14) and C2 (HLA-C*02,04,05,06,15) 
groups, depending on the presence of Asparagine or 
Lysine at position 80, respectively. The study of the 
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interactions between a specific KIR and subsets of 
HLA-C allotypes (C1 and C2) was established according 
to the Campbell KS’s review scheme [35].
CD16A genotyping by sequence‑based typing
The genotyping of CD16A-158V/F and CD16A-48 leu-
cine (L)/arginine (R)/histidine (H) was performed on 
genomic DNA by polymerase chain reaction (PCR) using 
primers previously described [36]. Briefly, PCR reactions 
were set up with 50 ng of genomic DNA per 50 µl reac-
tion and amplified products were purified and sequenced 
using Big Dye Terminator Chemistry (Applied Biosys-
tems, Foster City, CA) on an ABI Prism 3130 Genetic 
Analyzer (PE Applied Biosystems). Sequencing reactions 
were purified, and the analysis of results was obtained by 
alignment of  the processed sequences and the reference 
human CD16A gene.
Statistical analysis
Pearson X2 test was used for comparison of the gene fre-
quency of the patient group with controls. Fisher’s exact 
test was used when the expected difference between the 
two groups was small. The odds ratio (OR) and its 95 % 
confidence intervals (CI) were calculated. A p value of 
0.05 or less was considered to be significant. The influ-
ence of KIR genes with or without association with their 
HLA-C ligands was assessed using the binary logistic 
regression analysis (IBM SPSS Statistics v.19). The SPSS 
statistical package, Version 19 for Windows, was used for 
data and statistical analysis. CD16A haplotype frequen-
cies were assessed by an expectation-maximum (EM) 
algorithm. Thus, samples containing one allele were con-
sidered homozygous, and that allele was counted twice in 
the analysis. For multilocus genotypic data, the maximum 
likelihood was estimated using an EM algorithm when 
the gametic phase was not known. To determine whether 
the observed diploid genotypes were the product of a 
random gamete union, the Hardy–Weinberg equilibrium 
was calculated by the Guo and Thomson exact test [37]. 
The analysis of molecular polymorphisms at CD16A-48 
and 158, within the population, was performed using the 
ARLEQUIN V.3.0 POPULATION GENETICS software.
Results
Association of five aKIRs of the B haplotype with a reduced 
susceptibility to CRC
The extent of KIR gene differences in 52 CRC patients 
and controls was assessed by SSP genotyping of 16 dif-
ferent NK receptor genes (data provided in Additional 
file  1: Table S1). To determine whether a distinct KIR 
haplotype frequency is associated with a reduced or 
increased risk for a genetic susceptibility to CRC, we 
compared the A and B haplotype frequencies of CRC 
patients with those of LCTRs. In both sample groups, the 
A/B haplotypes were the most represented (LCTR 70.5 % 
and CRC 73.1  %). Within the B haplotype, we consid-
ered different centromeric and telomeric genes, and we 
noted a reduced percentage of the C4T4 subtypes in CRC 
patients as compared to LCTR (5.8 vs. 16.4 %, Additional 
file  2: Table S2). More importantly, we found a signifi-
cantly increased frequency of aKIR genes (≥5) in the B 
haplotype of LCTRs than that of CRC patients (16.4 vs. 
3.9  %, p =  0.036, OR 0.204). These results were further 
validated when the frequency of aKIRs in the B haplotype 
of Italian historical controls [32] was compared to that of 
CRC patients (p =  0.0005), Table  2. These data suggest 
that the presence of ≥5 aKIR genes may protect healthy 
subjects from CRC.
Enhanced KIR2DL2 and KIR2DS2 allele frequencies, in the 
absence of their HLA‑C ligand, is associated with a reduced 
susceptibility to CRC
Since the NK receptor/HLA ligand interaction controls 
NK-cell function influencing both the licensing and 
intensity of the NK cell immune response, we examined 
such a combination in CRC patients and controls by their 
cognate HLA-C ligand. We found that both frequencies 
of single HLA-C alleles and groups of KIRs, categorized 
according to the allelic residues at position 80 (Asn/Lys), 
were not significantly different between CRC patients 
and controls. Nevertheless, there was a statistically 
Table 1 Demographic and  clinical characteristics of  52 
CRC patients (from Central Italy)
Gender n (%) Count, frequency (%)
Male 31 (59.6)
Female 21 (40.4)
Age average (years) ± standard deviation
 All patients 70.8 ± 11.1
 Male 74.1 ± 7.85
 Female 66.2 ± 13.63
Clinical tumor stage,  %
 I 15 (28.8)
 II 16 (30.8)
 III 15 (28.8)
 IV 4 (7.7)
 Unknown 2 (3.8)
Location,  %
 Ascending right colon 19 (36.5)
 Transverse colon 3 (5.8)
 Descending left colon 10 (19.2)
 Cecum 1 (1.9)
 Rectum 19 (36.5)
 Unknown 1 (1.9)
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positive trend toward an increased frequency of HLA-
C1 alleles Asn80 in CRC patients over LCTRs (59.6 vs. 
47.4 %, p = 0.07), Additional file 3: Table S3.
We then examined the frequency of KIR2DL1, 
KIR2DL2, KIR2DL3 and their corresponding aKIRs in the 
presence or absence of their HLA-C ligands. We found 
a significantly lower incidence of KIRDL2 gene (5.8 vs. 
LCTR 19.0 %, p = 0.04, OR 0.2616) and KIR2DS2 gene, 
(5.8 vs 13.8 % and vs. Fasano’s CTR 16.3 %, p = 0.05, OR 
0.3145), in the absence of their cognate HLA-C1 ligand, 
in CRC patients compared to local and historical controls 
[33]. These results suggest that the presence of KIR2DL2 
and KIR2DS2, in the absence of their respective HLA 
C1 ligands, may protect one from the disease (Table 3). 
The KIR2DS2 results were further supported by a binary 
logistic regression analysis (p = 0.008, OR  0.186).
The impact of CD16A‑48 allele variants on CRC genetic 
susceptibility and CRC pathological staging
To determine the role of CD16A genotypes in the genetic 
susceptibility to CRC and pathological stage, we com-
pared the 559G/T (158, V/F) and 230A/G/T (48, H/R/L) 
allele polymorphisms in CRC patients and LCTRs 
(Table  4). CD16A-48H was significantly associated with 
CRC (p = 0.05, OR  2.761) and stages III–IV (p = 0.03, 
OR    3.625). Considering CD16A allele polymorphisms 
in haplotype (Table  5), four CD16A-48/158 haplotypes 
(48T/158G, 48T/158T, 48A/158G, 48G/158G) were 
assessed. CD16A-48T/158G and 48T/158T haplotypes 
were the best represented (i.e. 42.6 and 41.0 % in LCTR) 
and CD16A-48H being completely linked to 158  V in 
CRC patients and LCTRs.
Discussion
Our study strengthens the protective role of NK cells 
in CRC that is supported by our KIR results in which a 
prevalence of the B haplotype hosting  ≥5 aKIR genes, 
KIR2DS2 and KIR2DL2, in the absence of their HLA-C 
ligands, protects one from developing CRC. On the con-
trary, the contribution of NK cells to the CD16A-48H 
genotype-increased susceptibility to CRC and its asso-
ciation with advanced stages of disease is not readily 
apparent.
It is noteworthy that most of the studies addressing 
the role of NK cells in CRC have been performed utiliz-
ing immunohistochemistry. This methodology provides 
Table 2 Activating KIR frequency in CRC patients and Italian controls
aKIRs CRC pts (n = 52) Local CTRS (n = 61) p value Caggiari CTRS (n = 69) p value
N % N % N %
4 16 30.8 24 39.3 NS 19 27.5 NS
5–6 2 3.9 10 16.4 0.036 19 27.5 0.0005
Table 3 Distribution of KIR/HLA-C combinations in CRC patients, local healthy samples and Italian controls
a Pearson Chi square test or Fisher’s exact test, as appropriate




p valuea OR Fasano, 2014 
(N = 270)
p valuea OR
N % N % N %
2DL1 HLA-C2+ 34 65.4 43 74.1 NS 187 69.3 NS
2DL1 HLA-C2− 17 32.7 13 22.4 NS 74 27.4 NS
2DL2 HLA-C1+ 28 53.8 26 44.8 NS 113 41.9 NS
2DL2 HLA-C1/C1 11 21.2 5 8.6 NS
2DL2 HLA-C1− 3 5.8 11 19.0 0.047 0.2616 43 16.0 0.08
2DL3 HLA-C1+ 40 76.9 35 60.3 NS 183 67.8 NS
2DL3 HLA-C1− 6 11.5 11 19.0 NS 51 18.8 NS
2DS1 HLA-C2+ 13 25.0 22 37.9 NS 68 25.2 NS
2DS1 HLA-C2− 7 13.5 6 10.3 NS 29 10.7 NS
2DS2 HLA-C1+ 30 57.7 24 41.4 NS 112 41.5 0.033 1.9237
2DS2 HLA-C1− 3 5.8 8 13.8 NS 44 16.3 0.05 0.3145
2DS2 AND 2DS3 HLA-C1+ 16 30.8 14 24.1 NS
2DS2+ , KIR2DL2 or 2DL3+ , C group 1+ 30 57.7 23 39.7 0.08
2DL2 and 2DS2+ , C group 1 − 2 3.8 8 13. 8 0.09
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relevant information about the qualitative and quantita-
tive aspects of NK cell infiltration in the CRC microenvi-
ronment which can be correlated with the clinical course 
of disease. However, it cannot be utilized to identify 
healthy subjects at risk of developing disease. To this end, 
KIR genotyping may provide useful information about 
the possibility to determine a healthy subject at genetic 
risk of CRC.
In this study, we have compared the KIR genotype 
allele frequency of CRC patients to that of healthy local 
and historical controls, expecting to find a reduced 
allele frequency of activating KIRs and inhibitory KIRs, 
in the absence of their HLA-C ligands in CRC patients. 
In support of our hypothesis, we found a significantly 
reduced frequency of ≥5 aKIRs, belonging to the B hap-
lotype, in CRC patients when compared to LTCRs. In 
agreement with our study, other additional scientific 
reports, performed by KIR genotyping of CRC patients, 
have demonstrated an association of multiple aKIRs 
with long-term disease-free survival [38] and favorable 
responses to chemotherapy in patients with metastatic 
CRC [27]. An obvious interpretation of these data is that 
the presence of multiple KIRs may overcome the inhibi-
tory effects of the KIRs on NK cells increasing the level of 
NK cell activation. On the other hand, it has been shown 
that NK cells are capable of eliminating autologous CRC 
Table 4 Distribution of CD16A-48 and -158 genetic polymorphisms in Italian local controls and CRC patients





p value OR Grade I–II (n = 31)
N (%)




 CD16A-559T/T 5 (8.2) 4 (7.7) NS NS 2 (6.5) NS 2 (10.5) NS NS
 CD16A -559G/T 40 (65.6) 32 (61.5) NS NS 20 (64.5) NS 11 (57.9) NS NS
 CD16A -559G/G 16 (26.2) 16 (30.8) NS NS 9 (29.0) NS 6 (31.6) NS NS
 CD16A -559GT + TT 47 (74.6) 36 (69.2) NS NS 22 (71.0) NS 13 (68.4) NS NS
Allele
 CD16A -V158 (G) 72 (59.0) 64 (61.5) NS NS 38 (61.3) NS 23 (60.5) NS NS
 CD16A -F158 (T) 50 (41.0) 40 (38.5) NS NS 24 (38.7) NS 15 (39.5) NS NS
AA48
 CD16A -230A/G 0 1 (1.9) NS NS 0 NS 1 (5.3) NS NS
 CD16A -230G/T 10 (16.4) 5 (9.6) NS NS 2 (6.5) NS 3 (15.8) NS NS
 CD16A -230G/G 2 (3.3) 0 NS NS 0 NS 0 NS NS
 CD16A -230T/T 43 (70.5) 34 (65.4) NS NS 21 (67.7) NS 11 (57.9) NS NS
 CD16A -230A/Ta 6 (9.8) 12 (23.1) 0.07 NS 7 (22.6) NS 5 (26.3) NS NS
Allele
 CD16A -H48 (A)a 6 (4.9) 13 (12.5) 0.05 2.761 7 (11.3) NS 6 (15.8) 0.037 3.625
 CD16A -R48 (G) 14 (11.5) 6 (5.8) NS 3 (4.8) NS 3 (7.9) NS
 CD16A -L48 (T) 102 (83.6) 85 (81.7) NS 52 (83.9) NS 29 (76.3) NS
Table 5 Distribution of  CD16A-48 and  -158 haplotype frequencies in  Italian LCTR and  CRC patients, also distinguished 
for tumor grading
§  CD16-48A/158G OR 3.625
^ OR 2.7619
a Patients with known staging included in the study (N = 50)
b Pearson X2 test: FCGR3A-48A/158G vs 48G/158G haplotype p = 0.0256
CD16A Haplotype LCTR HF (n = 61) CRC HF (n = 52) p valueb Grade I–IIa (n = 31)
(af %)
P valueb Grade III–IVa (n = 19)
(af %)
p valueb
48T-158G (48L158 V) 0.42623 ± 0.045824 0.432692 ± 0.049342 NS 45.2 NS 36.8 NS
48T-158T (48L158F) 0.409836 ± 0.047115 0.384615 ± 0.047437 NS 38.7 NS 39.5 NS
48A-158G (48H158 V) 0.049180 ± 0.01791 0.12500 ± 0.033282 0.05^ 11.3 NS 15.8 0.037§
48G-158G (48R158 V) 0.114754 ± 0.026747 0.057692 ± 0.02222 NS 4.8 NS 7.9 NS
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cells [39]. According to the missing self-hypothesis, an 
enhanced level of NK cell activation may also be applied 
to the interpretation of the protective effect of KIR2DL2 
in healthy subjects, lacking their HLA-C1 ligand genes. 
In contrast, the analysis of the significance of KIR2DS2 
is harder to comprehend since it is not clear whether 
KIR2DS2 can activate NK cells in the absence of their 
HLA-C1 ligands.
The unique protective role of KIR2DL2 over the other 
KIRs may rely on the fact that KIR2DL2 is one of the most 
common KIR, nearly present in all individuals. Moreover, 
KIR2DL2 is also expressed by NK-T lymphocytes lead-
ing to an increased number of effector cells with anti-
CRC potential [40]. The protective role of KIR2DL2, in 
the absence of the HLA-C1 ligands, is not restricted to 
CRC but is also demonstrated in inflammatory bowel 
disease, including Crohn’s disease [41], underlying the 
importance of this KIR in NK cell immunity. In contrast, 
it is quite difficult to distinguish the role of KIR2DS2 
from that of KIR2DL2. Considering the protective effect 
is achieved in the absence of HLA-C1 ligands, while an 
active KIR2DS2 needs to bind the HLA-C1 ligands, there 
is a chance that this effect may not be related to KIR2DS2 
but is rather restricted to the influence of KIR2DL2 gene 
[42].
The complexity of this topic is underlined by the evi-
dence that the presence of ≥5 aKIRs is associated with 
human papilloma virus-induced cervical neoplasia [43]. 
Furthermore, a second study has shown that the pres-
ence of an increased number of aKIR genes is also found 
to be associated with the Epstein-Barr virus- linked naso-
pharyngeal carcinoma (NPC) [44].
Thus, the presence of ≥5 activating KIRs has a differ-
ent effect in solid tumors being protective in CRC and 
predisposing in cervical and nasopharyngeal carcino-
mas. One can speculate that this difference may reflect 
the possibility that NK cells are involved in the genera-
tion of two types of inflammation with opposite effects 
on tumor growth and development. In this context, NK 
cells may enhance the anti-CRC effect of CD8 + T cells 
by releasing interferon γ which up-regulates the expres-
sion of the HLA-class I and class II on the surface of CRC 
cells [45]. In contrast, NK cell activation, following virus-
induced malignancies, such as EBV or HPV, may trigger 
mechanism(s) of tumor immunoevasion from the NK 
cell immune surveillance. On the other hand, it has been 
clearly shown that NK cells can damage dendritic cells 
and macrophages, both involved in the presentation of 
tumor-associated antigen(s) to T cells [46].
The extent of ADCC mediated by CD16A, in the pres-
ence of mAbs, depends on the cell types including NK 
cells, monocytes, and granulocytes and CD16A polymor-
phisms. This is because the latter possesses the ability 
to bind the Fc fragment of mAbs with different affinity, 
affecting the extent of ADCC against tumor cells [47, 
48]. Then, guided by recent findings indicating that some 
CD16A polymorphisms predict the therapeutic effec-
tiveness of cetuximab in EGFR+  cancer patients [49], 
we found that only CD16A-48H gene variant is involved, 
being more associated with CRC patients and advanced 
stages of CRC. This association may reflect a status of 
immunodeficiency in CRC patients since the presence of 
CD16A-48H gene is linked to patients with episodes of 
recurrent viral infection of the respiratory tract support-
ing an in vivo NK cell abnormality [50]. By the available 
data, it is not possible to identify a cause/effect relation-
ship between CD16A-48H phenotype and NK cell immu-
nodeficiency. However, the presence of CD16A-48H 
results in a loss of the Leu11c/B73.1 epitope on NK cells 
that leads to the inhibition of the IgG binding to the 
CD16A [51, 52]. In this light, we speculate that CD16A-
CD48H may favor CRC development by an impaired 
ADCC against CRC cells.
Conclusions
Our study sustains the possibility that aKIR genotyping 
of the B haplotype, KIR2DL2 and HLA-C1 may be uti-
lized to identify healthy individuals at reduced risk of 
developing CRC, while the genotyping of the CD16A-
158V/48H haplotype is of interest for the identification of 
those at increased risk of CRC and tumor staging.
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